* Avoid cold weather. * Treat the underlying lymphoma. * No cold drinks; all drinks should be at room temperature (or above). * Requires heater to maintain temperature in cold places. Treatment with rituximab has been described. The treatment of<unk>  depends on many factors including the severity of the condition, the signs and symptoms present in each person, and the underlying cause. For example, in those affected by secondary<unk> , it is important to diagnose and treat the underlying condition which may include certain types of cancer; bacterial, viral, or parasitic infections; and/or other autoimmune<unk> . People with few symptoms and/or mild anemia may not require any specific treatment. These cases are often managed by simply avoiding exposure to the cold. In severe cases of hemolysis, medical interventions may be necessary. Rituximab (an antibody that selectively reduces specific types of immune cells) is effective in about 60% of cases of severe<unk> . Medical researchers have found the response to rituximab is seen on average within 1 to 2 months of treatment and the effect of the treatment lasts for about 1 to 2 years. Rituximab may be used after a second and even a third relapse, however the success rate is less. Combined treatment with rituximab and fludarabine has resulted in higher response rates (76% of cases) and longer periods of remissions (on average, 6.5 years). However the combined treatment may include serious side effects so is presently only recommended when rituximab has not worked alone. Finally, plasmapheresis, which involves filtering blood to remove antibodies, may be useful in acute hemolytic crisis and before surgery requiring hypothermia, however its effect is only short term. Removing the spleen is not recommended for<unk> . In addition, because severe<unk>  requires very high doses of corticosteroids (levels not considered safe), corticosteroid treatment is no longer a recommended treatment in severe cases. Several possible therapies have been reported in a few case reports to have successfully treated people who are not responding to the treatments listed above. However more studies need to be performed before the safety and effectiveness of these therapies can be determined. Sutimlimab (Enjaymo) was approved for medical use in the United States in February 2022.
Cold agglutinin disease
Atypical hemolytic uremic syndrome
MERRF syndrome
Serum sickness
Cold autoimmune hemolytic anemia
Michels Caskey syndrome
Hennekam syndrome
Uddanam nephropathy